Can a targeted pill boost Chemotherapy's punch against a rare lymphoma?

NCT ID NCT07730515

First seen Jul 28, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This trial is investigating whether adding an experimental drug called XNW5004 to standard chemotherapy (CHOP or CHOEP) can help people newly diagnosed with peripheral T-cell lymphoma, an aggressive type of non-Hodgkin lymphoma. The study will enroll about 176 adults aged 18 to 75 who have not yet received treatment for their disease. Researchers aim to find the safest dose of XNW5004 and see if the combination leads to better tumor shrinkage compared to chemotherapy alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
XNW5004 combined with CHOP or CHOEP chemotherapy
What this could lead to
If successful, this combination could offer a more effective first-line treatment for peripheral T-cell lymphoma, potentially improving response rates and long-term outcomes.
What could go wrong
This is an early-phase trial, so the safety and effectiveness of XNW5004 in this setting are not yet established. Adding a new drug to chemotherapy may increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.